Neuralized-2 Activators
Neuralized E3 Ubiquitin Protein Ligase 2 (NEURL2) is an enzyme that functions as an E3 ubiquitin-protein ligase in humans. E3 ligases are key components of the ubiquitin-proteasome system, which targets specific proteins for degradation by attaching ubiquitin molecules to them. This process, known as ubiquitination, is critical for numerous cellular processes, including cell cycle progression, apoptosis, and DNA repair.NEURL2 is part of the Neuralized family of E3 ubiquitin ligases, which are known for their role in the Notch signaling pathway, a highly conserved cellular signaling system that regulates cell-cell interactions necessary for proper embryonic development.
Recent studies have suggested a link between NEURL2 and human diseases, including cancer. For instance, NEURL2 has been identified as a potential tumor suppressor gene in hepatocellular carcinoma, the most common type of liver cancer. Moreover, it is believed that aberrant ubiquitination due to mutations in E3 ubiquitin ligases like NEURL2 can lead to the development of neurodegenerative diseases, such as Parkinson's and Alzheimer's.In summary, NEURL2 is an E3 ubiquitin-protein ligase with potential roles in various cellular processes and diseases. While its specific functions and substrates are not yet fully known, ongoing research highlights its importance in understanding the complex mechanisms of protein degradation, cellular signaling, and disease pathogenesis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A potent, reversible, and cell-permeable proteasome inhibitor. It blocks the degradation of ubiquitinated proteins, potentially enhancing NEURL2 activity by stabilizing its substrates. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A selective and reversible inhibitor of the 26S proteasome. It inhibits the degradation of ubiquitin-conjugated proteins, indirectly influencing NEURL2 function. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
An irreversible proteasome inhibitor. By inhibiting proteasome activity, it could indirectly modulate NEURL2-mediated ubiquitination processes. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
A selective and potent proteasome inhibitor. It blocks the degradation of ubiquitin-proteasome pathway substrates, potentially affecting NEURL2 activity. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
An irreversible proteasome inhibitor. It impairs the degradation of ubiquitinated proteins, which may impact NEURL2's role in ubiquitin tagging. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
A dipeptide boronic acid and proteasome inhibitor. It targets the ubiquitin-proteasome pathway, potentially influencing NEURL2 activity. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
An oral proteasome inhibitor. It disrupts the degradation pathway of ubiquitinated proteins, potentially altering NEURL2 function. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
A proteasome inhibitor. It affects the turnover of ubiquitinated proteins, potentially impacting NEURL2 activity. | ||||||
JNJ-26481585 | 875320-29-9 | sc-364515 sc-364515A | 5 mg 50 mg | $321.00 $1224.00 | ||
A natural product-based proteasome inhibitor. It could indirectly affect NEURL2 by altering proteasome-mediated protein degradation. | ||||||